AR113893A1 - Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción - Google Patents
Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producciónInfo
- Publication number
- AR113893A1 AR113893A1 ARP180103389A ARP180103389A AR113893A1 AR 113893 A1 AR113893 A1 AR 113893A1 AR P180103389 A ARP180103389 A AR P180103389A AR P180103389 A ARP180103389 A AR P180103389A AR 113893 A1 AR113893 A1 AR 113893A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- compound
- exhibiting
- degrees
- powder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
La presente descripción hace referencia a formas amorfas y polimórficas cristalinas de 2-metil-2-(3-metil-4-(4-(metilamino)-5-(trifluorometil)pirimidin-2-ilamino)-1H-pirazol-1-il)propanonitrilo o solvatos, tautómeros y cocristales o sales farmacéuticamente aceptables de este, así como a procesos para su elaboración. Reivindicación 1: Un compuesto cristalino, 2-metil-2-(3-metil-4-(4-(metilamino)-5-(trifluorometil)pirimidin-2-ilamino)-1H-pirazol-1-il)propanonitrilo, seleccionado de: un polimorfo de forma B que presenta un patrón de difracción de rayos X en polvo con picos característicos expresados en grados 2-q aproximadamente a 7,0, 7,3, 16,1, 16,3, 24,1, 25,1 y 26,6, un polimorfo de forma C que presenta un patrón de difracción de rayos X en polvo con picos característicos expresados en grados 2-q aproximadamente a 6,4, 15,1, 21,2, 25,7 y 27,8, y un polimorfo de forma D que presenta un patrón de difracción de rayos X en polvo con picos característicos expresados en grados 2-q aproximadamente a 9,2, 14,0, 14,8, 19,7 y 20,0.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589276P | 2017-11-21 | 2017-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR113893A1 true AR113893A1 (es) | 2020-06-24 |
Family
ID=66631734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180103389A AR113893A1 (es) | 2017-11-21 | 2018-11-20 | Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10370361B2 (es) |
| EP (1) | EP3717473B1 (es) |
| JP (1) | JP7303821B2 (es) |
| KR (1) | KR20200089713A (es) |
| CN (1) | CN111819174A (es) |
| AR (1) | AR113893A1 (es) |
| AU (1) | AU2018372180B2 (es) |
| BR (1) | BR112020010215A2 (es) |
| CA (1) | CA3083022A1 (es) |
| CL (1) | CL2020001346A1 (es) |
| CO (1) | CO2020006206A2 (es) |
| CR (1) | CR20200216A (es) |
| EA (1) | EA202091279A1 (es) |
| IL (1) | IL274824A (es) |
| JO (1) | JOP20200128A1 (es) |
| MA (1) | MA51222A (es) |
| MX (1) | MX2020005332A (es) |
| PE (1) | PE20210157A1 (es) |
| SG (1) | SG11202004733WA (es) |
| TW (1) | TWI823878B (es) |
| UA (1) | UA126414C2 (es) |
| WO (1) | WO2019104086A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3083022A1 (en) | 2017-11-21 | 2019-05-31 | Denali Therapeutics Inc. | Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production |
| EP3727377B1 (en) | 2017-12-20 | 2024-01-31 | Denali Therapeutics Inc. | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds |
| WO2023174946A1 (en) | 2022-03-15 | 2023-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Early and non-invasive method for assessing a subject's risk of having parkinson's disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201910912TA (en) | 2010-05-21 | 2020-01-30 | Incyte Corp | Topical Formulation for a JAK Inhibitor |
| CA2797947C (en) | 2010-06-04 | 2019-07-09 | Charles Baker-Glenn | Aminopyrimidine derivatives as lrrk2 modulators |
| GB201015949D0 (en) | 2010-09-22 | 2010-11-03 | Medical Res Council Technology | Compounds |
| HUE046617T2 (hu) * | 2010-11-10 | 2020-03-30 | Genentech Inc | Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok |
| BR112014011850B1 (pt) | 2011-11-29 | 2022-01-11 | Genentech, Inc | Derivados de aminopirimidina, seus usos, e composição farmacêutica |
| EP3121173A1 (en) | 2011-11-29 | 2017-01-25 | F. Hoffmann-La Roche AG | Aminopyrimidine derivatives as lrrk2 modulators |
| AR089182A1 (es) | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
| CA2850705C (en) | 2011-11-29 | 2020-03-10 | F. Hoffmann-La Roche Ag | 2-(phenyl or pyrid-3-yl)aminopyrimidine derivatives as kinase lrrk2 modulators for the treatment of parkinson's disease |
| MX363118B (es) * | 2012-05-03 | 2019-03-11 | Genentech Inc | Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2). |
| WO2013164323A1 (en) | 2012-05-03 | 2013-11-07 | F. Hoffmann-La Roche Ag | Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease |
| KR20230107407A (ko) | 2016-06-16 | 2023-07-14 | 데날리 테라퓨틱스 인크. | 신경퇴행성 장애의 치료에서 사용하기 위한 lrrk2 저해제로서피리미딘-2-일아미노-1h-피라졸 |
| CA3083022A1 (en) | 2017-11-21 | 2019-05-31 | Denali Therapeutics Inc. | Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production |
-
2018
- 2018-11-20 CA CA3083022A patent/CA3083022A1/en active Pending
- 2018-11-20 CN CN201880081321.5A patent/CN111819174A/zh active Pending
- 2018-11-20 MA MA051222A patent/MA51222A/fr unknown
- 2018-11-20 CR CR20200216A patent/CR20200216A/es unknown
- 2018-11-20 AU AU2018372180A patent/AU2018372180B2/en active Active
- 2018-11-20 UA UAA202003681A patent/UA126414C2/uk unknown
- 2018-11-20 US US16/197,037 patent/US10370361B2/en active Active
- 2018-11-20 KR KR1020207017598A patent/KR20200089713A/ko not_active Application Discontinuation
- 2018-11-20 TW TW107141257A patent/TWI823878B/zh active
- 2018-11-20 WO PCT/US2018/062102 patent/WO2019104086A1/en active Application Filing
- 2018-11-20 EP EP18881859.5A patent/EP3717473B1/en active Active
- 2018-11-20 PE PE2020000558A patent/PE20210157A1/es unknown
- 2018-11-20 MX MX2020005332A patent/MX2020005332A/es unknown
- 2018-11-20 BR BR112020010215-6A patent/BR112020010215A2/pt unknown
- 2018-11-20 EA EA202091279A patent/EA202091279A1/ru unknown
- 2018-11-20 JO JOP/2020/0128A patent/JOP20200128A1/ar unknown
- 2018-11-20 SG SG11202004733WA patent/SG11202004733WA/en unknown
- 2018-11-20 JP JP2020545076A patent/JP7303821B2/ja active Active
- 2018-11-20 AR ARP180103389A patent/AR113893A1/es unknown
-
2019
- 2019-06-20 US US16/447,713 patent/US10851088B2/en active Active
-
2020
- 2020-05-20 IL IL274824A patent/IL274824A/en unknown
- 2020-05-21 CO CONC2020/0006206A patent/CO2020006206A2/es unknown
- 2020-05-21 CL CL2020001346A patent/CL2020001346A1/es unknown
- 2020-11-27 US US17/105,870 patent/US11427571B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202004733WA (en) | 2020-06-29 |
| UA126414C2 (uk) | 2022-09-28 |
| MX2020005332A (es) | 2021-01-08 |
| MA51222A (fr) | 2020-10-07 |
| EP3717473B1 (en) | 2024-01-10 |
| IL274824A (en) | 2020-07-30 |
| AU2018372180A1 (en) | 2020-06-18 |
| EP3717473A1 (en) | 2020-10-07 |
| JOP20200128A1 (ar) | 2020-05-21 |
| US10370361B2 (en) | 2019-08-06 |
| WO2019104086A1 (en) | 2019-05-31 |
| CL2020001346A1 (es) | 2020-11-20 |
| US20210087176A1 (en) | 2021-03-25 |
| CN111819174A (zh) | 2020-10-23 |
| AU2018372180B2 (en) | 2023-08-17 |
| KR20200089713A (ko) | 2020-07-27 |
| EP3717473A4 (en) | 2021-07-07 |
| CO2020006206A2 (es) | 2020-08-10 |
| CA3083022A1 (en) | 2019-05-31 |
| US10851088B2 (en) | 2020-12-01 |
| US11427571B2 (en) | 2022-08-30 |
| JP2021504450A (ja) | 2021-02-15 |
| PE20210157A1 (es) | 2021-01-26 |
| JP7303821B2 (ja) | 2023-07-05 |
| BR112020010215A2 (pt) | 2020-11-03 |
| TW201925190A (zh) | 2019-07-01 |
| CR20200216A (es) | 2021-03-19 |
| TWI823878B (zh) | 2023-12-01 |
| US20190194170A1 (en) | 2019-06-27 |
| US20190315723A1 (en) | 2019-10-17 |
| EA202091279A1 (ru) | 2020-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19036765A (es) | PROCESO PARA LA PREPARACION DE PIRAZOLO[1,5-a]PIRIMIDINAS Y SALES DE ESTAS | |
| WO2017075629A3 (en) | Wee 1 kinase inhibitors and methods of making and using the same | |
| GEP20197011B (en) | Heteroaryl compounds for kinase inhibition | |
| ZA201700035B (en) | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof | |
| AR113893A1 (es) | Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción | |
| UY36112A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| CR20120469A (es) | Compuesto de pirazol-4-il-heterociclil-carboxamida y métodos de uso | |
| AR096758A1 (es) | Inhibidores cristalinos de bromodominios | |
| AR106612A1 (es) | Sales, formas cristalinas y composiciones farmacéuticas de 4-[2-(4-amino-piperidin-1-il)-5-(3-fluoro-4-metoxi-fenil)-1-metil-6-oxo-1,6-dihidro-pirimidin-4-il]-2-fluorobenzonitrilo como inhibidor de demetilasa 1 específica de lisina | |
| ZA201904402B (en) | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease | |
| ES2421956B1 (es) | Nueva forma cristalina de sulfato de sitagliptina | |
| AR100818A1 (es) | N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida | |
| CL2017000682A1 (es) | Compuestos novedosos de imidazopiridazina y su uso. | |
| PH12015502122A1 (en) | Sovaprevir polymorphs and methods of manufacturing thereof | |
| AR103444A1 (es) | Forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos | |
| CR20150659A (es) | Derivados de prodroga de triazolpiridinas sustituidas | |
| BR112018012095A2 (pt) | formas sólidas de compostos substituidos de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina | |
| AR098762A1 (es) | Polimorfos de 2-(4-(2-(1-isopropil-3-metil-1h-1,2,4-triazol-5-il)-5,6-dihidrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-il)-1h-pirazol-1-il)-2-metilpropanamida, métodos de producción, y usos farmacéuticos de los mismos | |
| ES2489467T3 (es) | Polimorfo novedoso del clorhidrato del éster (6-dimetilaminometil-2-naftalenílico) del ácido (4-hidroxicarbamoilfenil)-carbámico | |
| AR107441A1 (es) | Forma cristalina de cobicistat | |
| HK1221225A1 (zh) | -二氨基吡唑激酶抑制劑的藥學上可接受的鹽 | |
| BR112021018357A2 (pt) | Forma cristalina de inibidor de fosfodiesterase, método de preparação para a mesma e uso da mesma | |
| CO2017005357A2 (es) | Un proceso para la fabricación de idalopirdina | |
| AR103506A1 (es) | Formas sólidas de ácido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido)acético, sus composiciones y usos | |
| Tadpetch | Synthesis of Anti-Neuroinflamatory Tetrahydropyranyl Diarylheptanoids |